Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OL-108 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and 1 more, sponsored by Beijing Gaobo Hospital. Primary endpoints: Dose-limiting toxicity and Treatment emergent adverse event incidence and severity up to 2 years. Started Jun 2025; status: recruiting.
02
Drugs
OL-108
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06980597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980597.